The 2022 impact factor for Molecular Therapy - Nucleic Acids is 8.8.
This metric serves as a key indicator of a journal's influence within its scientific field, reflecting the average number of times articles published in the journal are cited by other researchers over a specific period.
Here is a summary of the journal's impact factor:
| Journal Name | Impact Factor (2022) | Publisher | Primary Focus |
|---|---|---|---|
| Molecular Therapy - Nucleic Acids | 8.8 | Cell Press | Gene, RNA, and Oligonucleotide Therapies |
Understanding Journal Impact Factors
The Impact Factor (IF) is a quantitative measure that helps evaluate the relative importance of a journal within its field. Calculated annually by Clarivate Analytics, it reflects the average number of citations received by articles published in that journal during the two preceding years.
- Influence Metric: A higher impact factor generally indicates that the journal's articles are more frequently cited and, therefore, are considered more influential in the scientific community.
- Annual Calculation: The IF is released annually as part of the Journal Citation Reports (JCR), providing an up-to-date assessment of journal performance.
- Field-Specific Comparison: It is crucial to compare impact factors only among journals within the same or closely related disciplines, as citation patterns and rates can vary significantly across different scientific fields.
- Research Evaluation: Researchers and academic institutions often use impact factors, among other criteria, when deciding where to submit their work or when evaluating scholarly output.
About Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids is a prominent peer-reviewed scientific journal dedicated to the advancement of nucleic acid-based therapeutics. Published by Cell Press, it is part of the esteemed Molecular Therapy family of journals. The journal covers a broad spectrum of research, from fundamental discoveries to translational studies and clinical applications, focusing on:
- Gene editing technologies
- RNA interference
- Aptamers
- Oligonucleotide-based drugs
- Delivery systems for nucleic acids
- Other innovative approaches leveraging nucleic acids for therapeutic purposes
For more comprehensive details regarding the journal's scope and aims, further information can be found on the Molecular Therapy Family of Journals page on Cell Press.
